Ubs Group Ag Cel Sci Corp Put Options Transaction History

Ubs Group Ag

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2021 Aug 13, 2021	BUY	$8.68 - $27.49 $6.73 Million - $21.3 Million	775,800 Added 95.71%	1,586,400 $13.8 Million
Q1 2021 May 12, 2021	BUY	$12.0 - $27.64 $9.49 Million - $21.9 Million	790,700 Added 3973.37%	810,600 $12.3 Million
Q4 2020 Feb 11, 2021	SELL	$11.05 - $16.62 $332,605 - $500,262	-30,100 Reduced 60.2%	19,900 $232,000
Q2 2020 Jul 31, 2020	BUY	$9.75 - $17.6 $487,500 - $880,000	50,000 New	50,000 $746,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.